NASDAQ:CERCCerecor Stock Price, Forecast & News

$3.23

+0.31 (+10.62 %)

(As of 06/1/2020 04:00 PM ET)

Add

Compare

Today's Range

$2.62

Now: $3.23▼

$3.67

50-Day Range

$2.16

MA: $2.48▼

$2.93

52-Week Range

$1.52

Now: $3.23▼

$6.19

Volume1.10 million shs

Average Volume168,337 shs

Market Capitalization$192.53 million

P/E RatioN/A

Dividend YieldN/A

Beta1.88

Cerecor Inc., a pharmaceutical company, focuses on pediatric health care. Its lead product portfolio includes prescribed dietary supplements, such as Poly-Vi-Flor and Tri-Vi-Flor; and prescription drugs, such as Millipre, Ulesfia, Karbinal ER, AcipHex Sprinkle, and Cefaclor for oral suspension, as well as Flexichamber a medical device. The company is developing CERC-301, an orphan neurological indication for controlling neurologic adaptation; CERC-406 for the treatment of Parkinson's disease; CERC-425, an orally active small molecule; CERC-611, a drug candidate for the treatment of partial-onset seizures in epilepsy; and CERC-913, a protide nucleotide for the treatment of mitochondrial disorder. It also developing preclinical therapies CERC-801, CERC-802, and CERC-803 for the treatment of inherited metabolic disorders. The company was formerly known as Ceregen Corporation and changed its name to Cerecor Inc. in March 2011. Cerecor Inc. was founded in 2011 and is headquartered in Rockville, Maryland.

Beat the Market (BTM) Rank^™

3.4 Analyst's Opinion

Consensus Rating
Cerecor has received a consensus rating of Buy. The company's average rating score is 2.75, and is based on 3 buy ratings, 1 hold rating, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $10.50, Cerecor has a potential upside of 225.1% from its current price of $3.23.
Amount of Analyst Coverage
Cerecor has only been the subject of 3 research reports in the past 90 days.

2.9 Community Rank

Outperform Votes
Cerecor has received 175 “outperform” votes. (Add your “outperform” vote.)
Underperform Votes
Cerecor has received 131 “underperform” votes. (Add your “underperform” vote.)
Community Sentiment
Cerecor has received 57.19% “outperform” votes from our community.

MarketBeat's community ratings are surveys of what our community members think about Cerecor and other stocks. Vote “Outperform” if you believe CERC will outperform the S&P 500 over the long term. Vote “Underperform” if you believe CERC will underperform the S&P 500 over the long term. You may vote once every thirty days.

0.0 Dividend Strength

Dividend Yield
Cerecor does not currently pay a dividend.
Dividend Growth
Cerecor does not have a long track record of dividend growth.

5.0 Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Cerecor insiders have bought 6,825.31% more of their company's stock than they have sold. Specifically, they have bought $9,958,879.00 in company stock and sold $143,804.00 in company stock.
Percentage Held by Insiders
58.00% of the stock of Cerecor is held by insiders. A high percentage of insider ownership can be a sign of company health.
Percentage Held by Institutions
59.90% of the stock of Cerecor is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

0.6 Earnings and Valuation

Earnings Growth
Earnings for Cerecor are expected to grow in the coming year, from ($0.58) to ($0.49) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Cerecor is -10.77, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Cerecor is -10.77, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Cerecor has a P/B Ratio of 8.08. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Overall Beat the Market Rank^™

2.38 out of 5 stars

Industry, Sector and Symbol

Stock Exchange NASDAQ

Industry Pharmaceutical preparations

Sub-IndustryN/A

SectorMedical

Current SymbolNASDAQ:CERC

Previous Symbol

CUSIPN/A

CIK1534120

Webwww.cerecor.com

Phone410-522-8707

Debt

Debt-to-Equity RatioN/A

Current Ratio1.66

Quick Ratio1.66

Price-To-Earnings

Trailing P/E RatioN/A

Forward P/E RatioN/A

P/E GrowthN/A

Sales & Book Value

Annual Sales$6.75 million

Price / Sales28.52

Cash FlowN/A

Price / Cash FlowN/A

Book Value$0.40 per share

Price / Book8.08

Profitability

EPS (Most Recent Fiscal Year)($0.30)

Net Income$-16,070,000.00

Net MarginsN/A

Return on Equity-68.23%

Return on Assets-28.57%

Miscellaneous

Employees64

Outstanding Shares59,606,000

Market Cap$192.53 million

Next Earnings Date8/13/2020 (Estimated)

OptionableOptionable

Receive CERC News and Ratings via Email

Sign-up to receive the latest news and ratings for CERC and its competitors with MarketBeat's FREE daily newsletter.

Cerecor (NASDAQ:CERC) Frequently Asked Questions

How has Cerecor's stock been impacted by COVID-19 (Coronavirus)?

Cerecor's stock was trading at $2.41 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, CERC shares have increased by 34.0% and is now trading at $3.23. View which stocks have been most impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of Cerecor?

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Cerecor in the last year. There are currently 1 hold rating and 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Cerecor.

When is Cerecor's next earnings date?

Cerecor is scheduled to release its next quarterly earnings announcement on Thursday, August 13th 2020. View our earnings forecast for Cerecor.

How were Cerecor's earnings last quarter?

Cerecor Inc (NASDAQ:CERC) released its earnings results on Thursday, May, 7th. The company reported ($0.04) EPS for the quarter, beating the consensus estimate of ($0.12) by $0.08. The company earned $2.75 million during the quarter, compared to analyst estimates of $2.25 million. View Cerecor's earnings history.

What price target have analysts set for CERC?

4 brokers have issued 12 month target prices for Cerecor's stock. Their forecasts range from $10.00 to $12.00. On average, they expect Cerecor's stock price to reach $10.50 in the next twelve months. This suggests a possible upside of 225.1% from the stock's current price. View analysts' price targets for Cerecor.

What are Wall Street analysts saying about Cerecor stock?

Here are some recent quotes from research analysts about Cerecor stock:

1. Maxim Group analysts commented, "Cerecor reported positive Parkinson’s disease (PD)- related neurogenic orthostatic hypotension (nOH). Key takeaways from the data include demonstration of a rapid and sustained improvement in systolic blood pressure upon standing particularly in the highest dose group (20mg); >7mmHg with max improvement of 29.1mmHg." (7/2/2019)
2. LADENBURG THALM/SH SH analysts commented, "We reiterate our Buy rating and $8 PT. Full data set is consistent with interim data." (7/2/2019)

Has Cerecor been receiving favorable news coverage?

Headlines about CERC stock have been trending very negative recently, InfoTrie Sentiment Analysis reports. The research group identifies positive and negative media coverage by monitoring more than six thousand blog and news sources in real-time. The firm ranks coverage of companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Cerecor earned a news sentiment score of -3.0 on InfoTrie's scale. They also gave media coverage about the company a news buzz of 0.0 out of 10, meaning that recent media coverage is extremely unlikely to have an impact on the stock's share price in the next several days. View the latest news aboutCerecor.

Who are some of Cerecor's key competitors?

Some companies that are related to Cerecor include Collegium Pharmaceutical (COLL), Cara Therapeutics (CARA), Akero Therapeutics (AKRO), Molecular Templates (MTEM), Kadmon (KDMN), Eagle Pharmaceuticals (EGRX), Retrophin (RTRX), Kala Pharmaceuticals (KALA), Ardelyx (ARDX), Provention Bio (PRVB), Homology Medicines (FIXX), G1 Therapeutics (GTHX), Vanda Pharmaceuticals (VNDA), Assembly Biosciences (ASMB) and Morphic (MORF). View all competitors.

What other stocks do shareholders of Cerecor own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Cerecor investors own include Inovio Pharmaceuticals (INO), Catalyst Pharmaceuticals (CPRX), Opko Health (OPK), Agile Therapeutics (AGRX), Alibaba Group (BABA), Ring Energy (REI), Ring Energy (REI), Voyager Therapeutics (VYGR), Cidara Therapeutics (CDTX) and Canopy Growth (CGC).

Who are Cerecor's key executives?

Cerecor's management team includes the following people:

Ms. Mariam E. Morris, Consultant (Age 51)
Dr. Simon C. Pedder Ph.D., Exec. Chairman (Age 58)
Mr. Joseph M. Miller CPA, Chief Financial Officer (Age 45)
Dr. Solomon H. Snyder, Founder and Chairman of Scientific Advisory Board (Age 80)
Dr. Barbara S. Slusher, Founder and Member of Scientific Advisory Board (Age 54)

What is Cerecor's stock symbol?

Cerecor trades on the NASDAQ under the ticker symbol "CERC."

Who are Cerecor's major shareholders?

Cerecor's stock is owned by a number of institutional and retail investors. Top institutional investors include BlackRock Inc. (2.14%), Ikarian Capital LLC (0.95%), State Street Corp (0.67%), Geode Capital Management LLC (0.45%), Nuveen Asset Management LLC (0.12%) and Invesco Ltd. (0.10%). Company insiders that own Cerecor stock include Armistice Capital Master Fund, Armistice Capital, Llc, Cerecor Inc, James Archie Harrell Jr, Joseph M Miller, Matthew V Phillips, Pericles Calias and Simon Pedder. View institutional ownership trends for Cerecor.

Which major investors are selling Cerecor stock?

CERC stock was sold by a variety of institutional investors in the last quarter, including BlackRock Inc., Spark Investment Management LLC, JPMorgan Chase & Co., and UBS Group AG. View insider buying and selling activity for Cerecor.

Which major investors are buying Cerecor stock?

CERC stock was acquired by a variety of institutional investors in the last quarter, including Squarepoint Ops LLC, Ikarian Capital LLC, State of Tennessee Treasury Department, Geode Capital Management LLC, Los Angeles Capital Management & Equity Research Inc., Nuveen Asset Management LLC, Invesco Ltd., and State Street Corp. Company insiders that have bought Cerecor stock in the last two years include Armistice Capital Master Fund, Armistice Capital, Llc, James Archie Harrell Jr, Joseph M Miller, Matthew V Phillips, Pericles Calias, and Simon Pedder. View insider buying and selling activity for Cerecor.

How do I buy shares of Cerecor?

Shares of CERC can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Cerecor's stock price today?

One share of CERC stock can currently be purchased for approximately $3.23.

How big of a company is Cerecor?

Cerecor has a market capitalization of $192.53 million and generates $6.75 million in revenue each year. The company earns $-16,070,000.00 in net income (profit) each year or ($0.30) on an earnings per share basis. Cerecor employs 64 workers across the globe.

What is Cerecor's official website?

The official website for Cerecor is www.cerecor.com.

How can I contact Cerecor?

Cerecor's mailing address is 540 Gaither Road Suite 400, Rockville MD, 20850. The company can be reached via phone at 410-522-8707 or via email at [email protected]

This page was last updated on 6/1/2020 by MarketBeat.com Staff